TY - JOUR
T1 - In vitro pharmacodynamics and in vivo efficacy of fluconazole, amphotericin B and caspofungin in a murine infection by Candida lusitaniae
AU - Sandoval-Denis, Marcelo
AU - Pastor, F. Javier
AU - Capilla, Javier
AU - Sutton, Deanna A.
AU - Fothergill, Annette W.
AU - Guarro, Josep
N1 - Funding Information:
Funding : This work was partially funded by the Universitat Rovira i Virgili (Reus, Spain) .
PY - 2014/2
Y1 - 2014/2
N2 - The in vitro activities of fluconazole (FLC), amphotericin B (AmB) and caspofungin (CSP) were evaluated against three isolates of Candida lusitaniae using time-kill curves. AmB showed in vitro fungicidal activity, whilst FLC and CSP exerted mainly strain-dependent fungistatic activity. The in vivo efficacies of the three drugs were evaluated in a murine model of disseminated infection. The doses administered were FLC 50 mg/kg/day, AmB 0.8 mg/kg/day and CSP 5 mg/kg/day. All three drugs were able to reduce the fungal burden in the kidneys of infected mice, with AmB showing the highest efficacy, followed by CSP. At least in this model, FLC, AmB and CSP are good candidates for treating invasive infections by C. lusitaniae.
AB - The in vitro activities of fluconazole (FLC), amphotericin B (AmB) and caspofungin (CSP) were evaluated against three isolates of Candida lusitaniae using time-kill curves. AmB showed in vitro fungicidal activity, whilst FLC and CSP exerted mainly strain-dependent fungistatic activity. The in vivo efficacies of the three drugs were evaluated in a murine model of disseminated infection. The doses administered were FLC 50 mg/kg/day, AmB 0.8 mg/kg/day and CSP 5 mg/kg/day. All three drugs were able to reduce the fungal burden in the kidneys of infected mice, with AmB showing the highest efficacy, followed by CSP. At least in this model, FLC, AmB and CSP are good candidates for treating invasive infections by C. lusitaniae.
KW - Animal model
KW - Antifungal therapy
KW - Candida lusitaniae
KW - Fungal infection
KW - Murine
UR - http://www.scopus.com/inward/record.url?scp=84893699155&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84893699155&partnerID=8YFLogxK
U2 - 10.1016/j.ijantimicag.2013.10.024
DO - 10.1016/j.ijantimicag.2013.10.024
M3 - Article
C2 - 24360922
AN - SCOPUS:84893699155
SN - 0924-8579
VL - 43
SP - 161
EP - 164
JO - International Journal of Antimicrobial Agents
JF - International Journal of Antimicrobial Agents
IS - 2
ER -